These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 11288537)

  • 1. [When hypertension damages microcirculation. A-II-antagonist corrects damage, beta blocker does not].
    MMW Fortschr Med; 2001 Mar; 143(9):55. PubMed ID: 11288537
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
    [No Abstract]   [Full Text] [Related]  

  • 4. [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
    MMW Fortschr Med; 2002 Sep; 144(38):14. PubMed ID: 12395694
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
    Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B;
    J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
    Fossum E; Olsen MH; Høieggen A; Wachtell K; Reims HM; Ibsen H; Julius S; Kjeldsen SE
    J Hum Hypertens; 2004 Jun; 18(6):375-80. PubMed ID: 15057253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.
    Park JB; Intengan HD; Schiffrin EL
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):40-5. PubMed ID: 11967798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
    Nattel S
    Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):332-3. PubMed ID: 16265553
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
    J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LIFE Trial in 2004.
    Beevers DG
    J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
    [No Abstract]   [Full Text] [Related]  

  • 13. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
    Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
    de Boer RA; van Veldhuisen DJ; Gans RO; Gansevoort RT
    Ned Tijdschr Geneeskd; 2003 Jan; 147(3):96-9. PubMed ID: 12577767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results from the LIFE study: promising effects of new hypertensive agents].
    Nilsson P; Kahan T
    Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.
    Chern CM; Hsu HY; Hu HH; Chen YY; Hsu LC; Chao AC
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):169-74. PubMed ID: 16495752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
    Heinzl S
    Med Monatsschr Pharm; 2002 May; 25(5):149. PubMed ID: 12050919
    [No Abstract]   [Full Text] [Related]  

  • 18. [Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
    MMW Fortschr Med; 2004 Apr; 146(18):55. PubMed ID: 15366474
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.